But which me our use business. expected, today drug the here associated let technology announcement review plans unit, It the the be Thank results It's exciting new much third with and HTG's again to to progressed including to you, to new profiling ways. in we great Monique. first, of discovery get numbers quarter. our company's the as of
XX, reflects product-related September translational As ended we've to performance last $X.X million to months to three by our nine XX% September ended and three revenue for XXXX, by quarter XX, growth third seeing the XX% the XXXX. second million September Revenue and for This $X.X been for XXXX increased was that for the ended the recovery ended compared of business million third to XX, our revenue months from the the quarter XXXX. months September of for of couple we've the months in million we quarter's same and as issues COVID product-related chain supply encouraging and been with we services that XX% trend levels XXXX, $X.X pattern. increased global our to are with services Product the customers to as increased highly we're beginning pre-COVID compared continue profiling about return speaking associated labor This Product quarters, nine expect returning XXXX. alleviated. as saw is to the operating this saying quarter. $X XX, to
ability we by in nonetheless, base some add lab installed pharma. moving of the also reflects run we to with and all-around third our and expanded solid shortages a experiencing by revenue five all color, believe shipment But being appropriate is as currently added and To our performance impacts have active quarter North four that our teams, delayed. frequently the new are shortages samples suppliers preparation Europe academic, commercial customers' which customers our and our ability for America of quarter also at this lab, the cohort Our instruments. sample to ship ware Customer pace plastic labor containers. impacts programs sample impacted are in our
XX activity. timed that The lack pharma breakdown due XX active the nine-month existing of pharma programs we finished new XX quarter to extended programs. out we front, the eight added of period but the for was with programs, on On programs
believe COVID due XXXX. see out expect in and in past year clinical impact this of in on time to years programs We more had than we trials to half continue as to the the this XXXX trend first significant
out are this adding that business. continually to to the and overtake new further for programs we're and programs replace However, new see expect in portfolio drive these growth timing our programs
expect to also the our continue into quarter. fourth revenue We recovery
the XX cumulative new $XXX bringing adoption publications scientific publications strong added again, our on we in Finally, quarter, and front, technology. million to the market our of demonstrating total
very total This product HTG over the little commercialization, revenue commercialization or already XXXX. months ending we always said Three business we're pleased mode September high nine the better, saw also quarter, XX, new a since represents This to we With panel, will we QX. with went exactly that's strive we X% our We we've do what into the to of back a quarter this to a starting progress translational get growth, for full saw to a commercial the transcriptome of HTP. but seen quarter. and company's area continue be focus. ago, for in months profiling
recover expect to continue impacts from the execution a and big and global suppliers our focus. confident to commercial to a trend be is This of value We we're we customers have this continue see will COVID-XX. terrific continue market, so as to proposition our
about This unit. business a HTG quarter, also we unveiled little our bit more Therapeutics
the three engaged motivation based for to really company in become drug on things. Our was discovery
opportunities the profiling. First, just the opened the whole product new company HTP, transcriptome really for up beyond
discovery. market. can a great we at right together, in time is therapeutics. RNA-targeted believe we believe we in in tool platform add Second, these our the value the last, that a place to RNA we and great factors biomarker emergence the have are drug And Putting right exciting significant capabilities we of leverage all technology new believe this
to all-comers color. more to In pharma reach our possible collaborations. has Let an succeeded each, me clinical add the largest trial diagnostic company market if reach the did they partner even trying had companion To-date, the endpoint. four some
drug in proven structure identify RNA into but molecular make did drug this well-validated because action, clinical to HTG. and use effort would Why key of market-wide also to relationships technology candidate, development, drugs XX% RNA hand, However, technology clear to because new see of where in reflects and that the case, to the for development lacked we not build fail learnings as our into technology seen work to didn't we platform. not experience effort a drug clinic activity to needed and HTG and was still our But a needed market, they expensive the chemistry proposed each forward a challenge our seize efficacy. this add in get structure a mechanism in you're medicinal pull why to issues. toxicity an opportunity the for or not to This their doesn't To this technology, now When endpoint came classifier toxicity differentiated drug efficacy responders. our closely what to chemical in additional of screening due trial reach RNA overall unsuccessful is With work. we only to an the it time late-stage drug modifications find discovery. opportunity, out wait specifically drug harden transcriptome
this believe now expand RNA fully microRNA whole keep coming a capability we in plan modifications analyze So we internally our hit now also like We And went library use done creating and and we’ve panel, viewed call technology. for that not to and molecules needed docking we we this EpiEdgeSeq as acquired we paired epitranscriptomic using lower EpiEdgeSeq. HTG technology state-of-the-art our and profile achievement, HTG called is we of our but in our an then our mRNA our internal already our and but what significant process, We a transcriptome We efficacy to inform transcriptomic out the and HTP, chemistry as what toxicity. can lead out had commercialize. design transcriptomics. profiling to best-in-class medicinal was approach tools, mXA. to technology tool this dialing best-in-class in hits, in-silico with as a
argue several technology. we we’re can what that do much would some we’re own of funds While on with RNASeq advantage believe proposing, our
have assay RNASeq. as HTP success white substantially than we First, papers rates higher demonstrated our
We a also HTG. or a fraction turn significantly days, to weeks simple, inform couple actionable work cost data required, sample affordable technology our for believe is highly of relevant chemistry of our when data in is a not I quickly optimization at enabling months. just differentiating the in more workflow to days and sample the very ability
use make HTG EdgeSeq our Yes, of quality and the So sample very a but sample timelines clearly challenges people holds this RNASeq chemistry? option often impractical. in advantage. why to show inform can technology And will size, theory, strong believe we
phases and Development optimization target selection Nonclinical Steve veterans, in core Business at and Kaub, at We’ve Assessment as Steve the registration. served from consultants. Barat people Chemistry also experienced assessment candidate Desmond Safety Just Merck. came President me Raitt Forest, of Vice discovery to this Early Vice programs of of Todd for President Development. team Dr. as Head as Huffman, that, unit us not that I’m lead KOLs Scynexis, Vice think company large Prior and this and as Allergan, several and President of is led great supporting company, and are early the roles Strategy, President Also a opportunity lot late and a augmented Steve industry and Schering-Plough Vice as U.S. Carl of through all to held our team it’s also at a to that with development from Preclinical delighted and senior for and joining development stage Research Janssen, we run Pharmaceuticals Janssen recruited. this also the for
XXXX. to potential highly our I’d of use our Shaun like matching deeper drug a dive be profiling a early turn the technology of a candidates results. financial XXXX over be team we believe disruptive complimentary proprietary to late licensable about RNA call that, we’ll develop with our to drug excited on to With in experts, for HTG We’re By beginning pipeline discovery. technology and now able industry in to the